1. Home
  2. Live Updates
  3. Florent gros

Live Breaking News & Updates on Florent gros

Stay informed with the latest breaking news from Florent gros on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Florent gros and stay connected to the pulse of your community

Earlybird Health closes twice-larger second fund, will write bigger checks

Germany-based Earlybird Health announced the final closing of its second fund of €173 million (around $185 million). This is more than twice the size of Earlybird's first healthcare-focused fund.

Germany , United-kingdom , British , Thom-rasche , Florent-gros , Christoph-massner , Earlybird-health , Nasdaq , British-business-bank , While-earlybird-health , Germany-based-earlybird-health , British-patient-capital

Germany's Earlybird Health closes €173M healthcare fund; aims to invest in these healthcare sectors

Earlybird Health, a unit of Berlin-based VC firm Earlybird Venture Capital, announced that it has closed its latest healthcare fund at €173M. According to

Turkey , Germany , France , United-kingdom , Berlin , British , German , Christine-hockley , Christoph-straub , Florent-gros , Christoph-massner , Digital-west-fund

FDA Grants Orphan Drug Designation to KRP203 Following allo-HSCT in Patients with Hematologic Malignancies

This is KRP203’s second Orphan Drug Designation and it is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers.

Florent-gros , Priothera-ltd , Orphan-drug ,

Priothera – US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies

Priothera – US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies

Massachusetts , United-states , France , Dublin , Ireland , Boston , Sweden , Berlin , Germany , America , Florent-gros , Drug-administration

First patients enrolled for Priothera's mocravimod trial

Treatment is a maintenance therapy for certain patients with acute myeloid leukaemia - News - PharmaTimes

United-states , Israel , American , Florent-gros , Latin-american , Priothera- , Ocravimod- , Eukaemia ,

Priothera reveals positive mocravimod data

Therapy is well-tolerated in allogeneic haematopoietic cell transplantation (HCT) patients - News - PharmaTimes

Florent-gros , Elisabeth-kueenburg , Data- , Ocravimod- , Riothera ,

Priothera - Positive mocravimod Phase 1b clinical data published in Transplantation and Cellular Therapy

/PRNewswire/ -- Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod, announces...

Germany , United-states , Frazer-hall , Kilkenny , Ireland , Massachusetts , Boston , Sweden , Dublin , France , Berlin , American

ImCheck Closes Upsized EUR 96 Million (USD 103 Million)

Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C...

Wellington , New-zealand-general- , New-zealand , Paris , France-general- , France , Alexandria , Al-iskandariyah , Egypt , Munich , Bayern , Germany

Priothera Receives Fast Track Designation for mocravimod in Combination with Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Post Remission Therapy of Acute Myeloid Leukemia (AML) Patients

/PRNewswire/ -- Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, today...

Germany , Japan , Frazer-hall , Kilkenny , Ireland , Massachusetts , United-states , Boston , Sweden , Dublin , France , Berlin

New Investigational Drug for Acute Myeloid Leukemia Patients

Priothera Ltd. today announces that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed with the Company's Investigational New | New Investigational Drug for Acute Myeloid Leukemia Patients

Japan , Florent-gros , Priothera-ltd , Company-investigational-new-drug , Drug-administration , Investigational-new-drug , Acute-myeloid-leukemia ,